Alcohol Abuse and Osteoporosis

Today is World Osteoporosis Day – a day dedicated to the complications caused in osteoporosis, studies for the cause and effects, and the possible remedies that the researchers are seeking. Osteoporosis is a public health issue related to bones. It is marked by weakening of bones, loss of bone mass and frequent fractures. All around the world there are millions who either suffer directly or have a sufferer of osteoporosis with them. They are keen to find out how they can recover from this chronic disease.


Researchers have so far discovered certain key factors that can cause this disease and one of this is alcohol abuse. Consuming alcohol over the limits every day can be detrimental for the bones, as for other organs. Abuse causes bone toxicity rendering them to become weaker with time. The eventual result is frequent fractures that take ages to heal.

Researchers are readily calling for people to quit their booze and lead a healthy life.

Bentham Science plays its role in providing all important research studies to help the osteoporosis patients and to keep people from drinking. Find out the study, Pathogenesis of Alcohol-Induced Osteoporosis and its Treatment: A Review, published in the journal, Current Drug Targets.

World Osteoporosis Day 2017!


World Osteoporosis Day takes place every year on October 20, launching a year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and metabolic bone disease.

Bentham Science Publishers has various research articles dedicated to the Osteoporosis and bone diseases that can be found in the following journal:

Current Rheumatology Reviews

To Avail 20% Discount on related eBooks, kindly visit:

Bentham Science free trial in Institute of Biomedical Chemistry (IBMC), Russia!

Institute of Biomedical Chemistry (IBMC) concentrates 70 years of expertise in molecular bioscience, specifically focused on proteins as disease markers or drug targets. In 20-th century Institute discovered Angiotensin Converting Enzyme (ACE) to provide the cure for over 12 bln people suffering from high blood pressure. Nowadays Institute is focused on bioinformatics and omics-technology to contribute in international efforts for deciphering the Human Proteome. Research areas of IBMC comprise structural and functional organization of biological macromolecules, mechanisms of intermolecular recognition, computer-aided drug design and devices for prevention of health risks.


Upcoming Thematic Issue – Bioactive molecules from marine resource – Current Medicinal Chemistry


SMi EVENT – 7th annual Pharmaceutical Microbiology!

SMi Group is thrilled to present the 7th annual Pharmaceutical Microbiology taking place on 22nd – 23rd January 2018 in London, UK.

200 x 200 copy

SMi’s 7th annual Pharmaceutical Microbiology UK conference will provide attendees essential indicators for Quality Assurance and Quality Control whilst presenting that latest information on protecting pharmaceutical and healthcare products from spoilage by microorganisms, and protecting patients and consumers.

This 2018 event will provide an in-depth overview of the function of the pharmaceutical microbiologist and what they need to know, from regulatory filing and GMP, to laboratory design and management, and risk assessment tools and techniques. These key aspects are discussed through a series of dedicated presentations, keynote sessions and workshops, with topics covering biofilms, validation, data analysis, bioburden, toxins, microbial identification, mycoplasma testing, and contamination control.


  • Oliver Chancel, Sterility and Aseptic Process, Assurance Expert, Merial Sas
  • Andrew Bartko, Research Leader, Battelle Memorial Institute

Expert Speaker Line-Up Features:

  • Renate Rosengarten, Professor and Chair of Bacteriology and Hygiene, University of Veterinary Medicine Vienna
  • Ingo Spreitzer, Deputy Head Section Microbial Safety, Paul-Ehrlich Institute
  • Ruth Daniels, Senior Scientist Microbiology, Janssen
  • Jeremy Webb, Professor of Microbiology, Principal Investigator (Biofilms and Microbial Communities), University of Southampton
  • Shahram Lavasani, CEO & Founder, ImmuneBiotech

Exclusive highlights in 2018:

  • Hear about new mycoplasma testing methods to optimise contamination control
  • Gain insight from a regulatory perspective on ways to make testing methods compliant
  • Explore actual implementation of rapid microbial methods within a laboratory setting, that meet regulatory requirements
  • Gain an in-depth understanding of biofilms and why they pose such an issue in terms of drug development and delivery
  • Receive updates on the current research being done to circumvent the issues posed by biofilms

For more information visit the website at or contact the team on email: or call +44 (0) 207 827 6012

Journal: Current Pharmaceutical Biotechnology

EBook: Frontiers in Anti-Infective Drug Discovery 


Podcast: Cola Beverages: Clinical Uses versus Adverse Effects

Author(s): Ehsan Tafazoli Moghaddam, Ali Tafazoli.

For article details, visit:

Subscribe our YouTube channel

Testimonial by Cinthia de Carvalho Couto!

Cinthia de Carvalho Couto

Contributed Article: “Development Of Coffee Reference Material For Coffea Arabica And C. Canephora Blends

Highlighted Article –Ultrasound Assisted-synthesis and Biological Evaluation of Piperazinylprop- 1-en-2-yloxy-2H-chromen-2-ones as Cytotoxic Agents – Letters in Drug Design And Discovery

LDDD-14-12-Anna Pratima G. Nikalje

To access this article, please visit:

Open Access Article – Glucose Oxidase Production from Sustainable Substrates – Current Biotechnology

Journal:  Current Biotechnology

Author(s): Daniel P. Kiesenhofer, Robert L. Mach, Astrid R. Mach-Aigner.

Graphical Abstract:



Background: Glucose oxidase (GoxA) catalyzes the reaction from β-D-glucose to gluconic acid. It has a wide range of applications, for example as a sugar sensor for diabetes monitoring or as a prominent additive in food industry. The fungus Aspergillus niger naturally expresses and secretes GoxA. Currently, GoxA is produced by A. niger on yeast peptone dextrose media or by yeasts on media containing sugars in high concentration.

Objective: Trichoderma reesei is a well-studied, saprotrophic fungus that is used for industry-scale enzyme production due to its high secretory capacity. GoxA production in T. reesei could combine two promising aspects: high expression and secretion on the one hand, and the utilization of a sustainable and inexpensive carbon source, such as wheat straw or chitin, on the other hand.

Method: To evaluate if this is a feasible concept for GoxA production we applied four different expression systems: the constitutive promoter of the pyruvate kinase-encoding gene pki1 of T. reesei, the inducible promoters of the xylanase II-encoding gene xyn2 and of the cellobiohydrolase I-encoding gene cbh1, which is considered as one of the strongest promoters known in T. reesei, and finally, the promoter of the N-acetylglucosaminidase-encoding gene nag1 of Trichoderma harzianum.
Result: We discovered that an engineered variant of the cbh1 promoter led to higher yields of GoxA than the wild-type promoter did. This could be demonstrated in shake flask and bioreactor cultivation experiments. The obtained yields (between 28.90 U/ml and 39.00 U/ml) from wheat straw even exceeded the ones reported for A. niger.

Highlighted Article – Radiochemical Evaluation and In Vitro Assessment of the Targeting Ability of a Novel 99mTc-HYNIC-RGD for U87MG Human Brain Cancer Cells – Current Radiopharmaceuticals

CR-Articles_10-3-Nourollah Sadeghzadeh.jpg

To access this article, please visit: